First Manhattan’s Akari Therapeutics AKTX Stock Holding History

First Manhattan’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1	Closed	-$1K	–	1367
2017 Q4	$1K	Buy	+1	New	+$3.86K	﹤0.01%	1401

Other funds holding AKTX

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

First Manhattan's AKTX Position: Q1 2018 in Review

First Manhattan sold out of Akari Therapeutics (AKTX) in Q1 2018, closing a stake of 1 share — an estimated $1K sold.

First Manhattan first reported a position in AKTX in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2018.

First Manhattan reported no remaining Akari Therapeutics position as of Q1 2018 after selling out during the quarter.
First Manhattan sold 1 Akari Therapeutics share in Q1 2018, an estimated $1K.
First Manhattan first reported a position in Akari Therapeutics in Q4 2017 and held it in 1 quarter.
First Manhattan's Akari Therapeutics position peaked at $1K in Q4 2017.
9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2018.

Based on First Manhattan's 13F filing for Q1 2018, filed 20 Apr 2018.